Guidance on the use of vinorelbine for the treatment of advanced breast cancer
National Institute for Clinical Excellence
Record ID 32003000012
English
Authors' objectives:
To provide guidance on the use of vinorelbine for the treatment of advanced breast cancer.
Authors' recommendations:
Guidance: 1.1 Vinorelbine monotherapy is not recommended as a first-line treatment for advanced breast cancer.
1.2 Vinorelbine monotherapy is recommended as one option for second-line or later therapy for the treatment of advanced breast cancer when anthracycline-based regimens have failed or are unsuitable. The choice of appropriate second-line or later treatment for advanced breast cancer should be made jointly by the patient and the clinician responsible for treatment after an informed discussion of the relative benefits of the available drugs and their side-effect profiles.
1.3 The present state of evidence does not allow the Institute to recommend the routine use of vinorelbine combination therapies.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.nice.org.uk/cat.asp?c=44855
Year Published:
2002
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antineoplastic Agents
- Breast Neoplasms
Contact
Organisation Name:
National Institute for Clinical Excellence
Contact Address:
MidCity Place, 71 High Holborn, London WC1V 6NA, UK. Tel: +44 020 7067 5800; Fax: +44 020 7067 5801
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.